Sanofi Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (111)

Latest Posts

About This Stock More About This Stock
Daily Stock Analysis: Sanofi S.A.
Article By: Fredrik Arnold
Tuesday, July 19, 2022 3:00 AM EDT
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. It was founded in 1973 and is headquartered in Paris.
In this article: SNY
DarioHealth Enters Into Strategic Agreement With Sanofi U.S.
Article By: TalkMarkets Newswire
Tuesday, March 1, 2022 8:22 AM EDT
Novel Strategic Agreement focuses on commercial growth for Dario and the development of Digital Health Solutions on Dario’s platform.
In this article: SNY, DRIO Also: JNJ, PFE, BNTX
Sanofi SA: An Expected Move Towards The $52.90
Article By: AAATrade
Friday, February 4, 2022 6:55 AM EDT
Today we can expect a move towards the $52.90 resistance, possibly further into the $54 price range, anticipating positive news. 
In this article: SNY
Sanofi Acquires Translate Bio For $38 Per Share In Cash Or $3.2B
Article By: The Fly
Tuesday, August 3, 2021 6:03 AM EDT
Sanofi has entered into a definitive agreement with Translate Bio for $38.00 per share in cash, which represents a total equity value of $3.2B a fully diluted basis.
In this article: SNY, TBIO
Sanofi, GSK Start Final Testing Phase Of COVID-19 Vaccine
Article By: Benzinga
Thursday, May 27, 2021 9:00 AM EDT
Sanofi SA and GlaxoSmithKline plc have launched a Phase 3 trial for its recombinant COVID-19 vaccine candidate, which they hope to get approved by the end of 2021.
In this article: SNY, GSK

Latest Tweets for $SNY

No tweets yet!



There Is Beta In Protalix Stock Due To PRX-102
Paul McGee 8/28/2020 2:44:13 AM

Isn't that made by Sanofi $SNY?

Protalix BioTherapeutics Pipeline Progress
Harry Goldstein 8/10/2020 6:01:37 AM

#Protalix clearly has a lot of potential but there's a limited number of people who will need this drug. So the real question is how much of a dent will they put into #Sanofi's market share. $PLX $SNY

Protalix BioTherapeutics Pipeline Progress
Old Time Investor 8/3/2020 2:23:12 PM

My pleasure. What's more important than how prevalent the disease is, is how much money #Protalix can make on its new drug. It's competitor, #Sanofi ($SNY) makes $1 billion in revenue annually on their drug. Protalix's sounds like a more promising alternative. I'd definitely rate $PLX a buy.

1 to 3 of 3 comments